Tag Archives: lenvatinib

November, 2018

May, 2018

January, 2018

September, 2017

May, 2016

  • 16 May

    FDA Expands Approval of Eisai’s Lenvima in Kidney Cancer

    WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an …

January, 2016

  • 19 January

    Eisai’s Kidney Cancer Drug Receives Priority Review from the FDA

    WOODCLIFF LAKE, N.J., Jan. 17, 2016 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for lenvatinib for the potential treatment of patients with unresectable advanced or metastatic renal cell carcinoma (RCC) in combination with …